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ABSTRACT
Objective: To explore symptom appraisal and help-
seeking decisions among patients recently diagnosed
with melanomas, and to compare experiences of
people with ‘thinner’ (<1 mm) and ‘thicker’ (>2 mm)
melanomas, as thickness at diagnosis is an important
prognostic feature.
Methods: In-depth interviews with patients within
10 weeks of melanoma diagnosis explored the factors
impacting on their pathways to diagnosis. Framework
analysis, underpinned by the Model of Pathways to
Treatment, was used to explore the data with particular
focus on patients’ beliefs and experiences, disease
factors, and healthcare professional (HCP) influences.
Results: 63 patients were interviewed (29–93 years,
31 women, 30 thicker melanomas). All described their
skin changes using rich lay vocabulary. Many included
unassuming features such as ‘just a little spot’ as well
as common features of changes in size, colour and
shape. There appeared to be subtly different patterns of
symptoms: descriptions of vertical growth, bleeding,
oozing and itch were features of thicker melanomas
irrespective of pathological type. Appraisal was
influenced by explanations such as normal life
changes, prior beliefs and whether skin changes
matched known melanoma descriptions. Most
decisions to seek help were triggered by common
factors such as advice from family and friends.
11 patients reported previous reassurance about their
skin changes by a HCP, with little guidance on
monitoring change or when it would be appropriate to
re-consult.
Conclusions: Patients diagnosed with both thinner
and thicker melanomas often did not initially recognise
or interpret their skin changes as warning signs or
prompts to seek timely medical attention. The findings
provide guidance for melanoma awareness campaigns
on more appropriate images, helpful descriptive
language and the need to stress the often apparently
innocuous nature of potentially serious skin changes.
The importance of appropriate advice, monitoring and
safety-netting procedures by HCPs for people
presenting with skin changes is also highlighted.
INTRODUCTION
Diagnosing melanoma earlier is high on the
UK health policy agenda; it is estimated that
around 190 deaths from melanoma could be
avoided each year if survival rates in England
matched the best in Europe.1 Worldwide
Strengths and limitations of this study
▪ This study is the first exploration of symptom
appraisal and help seeking among people diag-
nosed with ‘thinner’ melanomas (T1, very good
prognosis, 5 year disease-free prospects 95%),
compared with those with ‘thicker’ melanomas
(T3 and T4, less good prognosis, 5 year disease-
free prospects <55%).
▪ The study did not identify clear discriminating
features in the diagnostic pathway, or features of
thinner versus thicker melanomas.
▪ The findings highlight a mismatch between the
information people need when assessing their
skin changes and the information and images
currently available, thus providing opportunities
to incorporate more appropriate descriptive lan-
guage, images and information into targeted
community awareness campaigns as well as by
the National Health Service (NHS) and charities
via their websites and promotional materials.
▪ A small but important minority of participants
did not have their developing melanomas recog-
nised during their first primary care consultation,
and were not provided with enough information
about ongoing assessment of further skin
changes or when to return to their clinician.
These ‘safety-netting’ opportunities could be
improved by more systematic approaches by
healthcare professionals.
▪ Using semistructured interviews close to diagno-
sis allowed in-depth exploration of the partici-
pants’ experiences and views, but the accounts
are necessarily retrospective and subject to recall
and framing bias.
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melanoma incidence rates are increasing faster than any
other solid tumour. In the UK the incidence has quad-
rupled since the 1970s2; similar incidence rises have
been reported across Europe,3 4 the USA5 and
Australia.6 In the UK there were more than 2209 deaths
and 12 800 new cases diagnosed in 2011, with a dispro-
portionately high rate among people aged less than
50 years.2 The most important prognostic factor is the
tumour thickness at diagnosis according to the Breslow
scale (T classiﬁcation).7 Patients with a primary melan-
oma ≤1 mm at diagnosis (T1) currently have 5-year
disease-free prospects of over 95%, while for tumours
≥2 mm at diagnosis this is lower, falling to <55% with
lymph node involvement but no metastatic spread.8
Tumour thickness is also associated with rapid growth
which occurs more frequently in elderly men.9
Timely diagnosis can be inﬂuenced by the diagnostic
skills of general practitioners (GPs). A recent analysis of
the Cancer Patient Experiences Survey 2009 and the
2010 RCGP cancer audit data reported that more than
90% of people diagnosed with melanoma were seen by
their GPs less than three times before diagnosis, com-
pared with 60–80% for the majority of cancer types.10
This suggests that most melanomas are recognised by
GPs and appropriately referred to specialist care in
England.
Timely diagnosis can also be inﬂuenced by people’s
symptom appraisal and help-seeking behaviour.
Compared with other cancers, people with melanoma
have among the longest time between ﬁrst noticing a
symptom and presenting to their GP,11 12 suggesting that
the major opportunity to diagnose melanoma earlier is
prompting earlier presentation to healthcare through
signs and symptom awareness campaigns.13 This requires
an understanding of how people interpret changes in
their moles or new lesions. We present ﬁndings from an
in-depth interview study with UK patients recently diag-
nosed with ‘thinner’ (T1) compared with ‘thicker’
primary melanomas (T3 and T4), which aimed to
explore the processes and experiences of symptom
detection and help-seeking decisions leading to melan-
oma diagnosis.
METHODS
Design and ethics
Semistructured face-to-face in-depth interviews were con-
ducted with adults diagnosed with invasive cutaneous
melanoma within the previous 10 weeks.
Setting and recruitment
Potential participants were identiﬁed and recruited by
the melanoma/skin cancer nurse specialists via the
weekly multidisciplinary team meetings of dermatolo-
gists, plastic surgeons and oncologists at two regional
hospitals: Cambridge University Hospitals NHS
Foundation Trust in the East of England, and the
Edinburgh Royal Inﬁrmary, NHS Lothian, Scotland.
These hospitals together serve a population of approxi-
mately 1.4 million, and the MDT meetings review more
than 400 new cases of invasive cutaneous melanoma
each year.
All adults aged 18 and above newly diagnosed with a
primary invasive cutaneous melanoma (staged as ≤1 mm
(T1, ‘thinner’) or ≥2 mm (T3 and T4, ‘thicker’) at the
two participating hospitals were eligible for inclusion
unless the melanoma/skin cancer nurse specialists felt
that they were not suitable on clinical grounds (other
severe physical or mental health conditions). Patients
were mailed an invitation letter with a patient informa-
tion sheet. As T3 and T4 melanomas are diagnosed at
about 25% of the rate of T1 melanomas, we recruited all
those with thicker melanomas who agreed to take part.
At the same time we purposively sampled people with
T1 melanomas by age, gender, location and season to
ensure that we had a broad range of views and experi-
ences, and we continued until saturation of data.
Reasons for not selecting patients for interview included:
sampling decisions (n=34), lost to follow-up (n=6) and
ill health (n=1).
Data collection
Interviews were undertaken between January 2012 and
January 2013. In each area an experienced researcher
used a semistructured approach with an interview sched-
ule informed from the literature,14 15 our collective
expertise from interviewing patients recently diagnosed
with other cancers,16 and a pilot study (n=17, conducted
during the early stages of the study, and including
patients interviewed >10 weeks post-diagnosis (n=12), or
with melanoma histology which did not ﬁt the inclusion
criteria (n=5, Breslow thickness 1–2 mm or indetermin-
ate)). The theoretical approach of the Model of
Pathways to Treatment17 18 (ﬁgure 1) was used to under-
pin the interview schedule, exploring the processes that
occurred within each time interval and focusing on: how
initial symptoms were noticed; personal risk perceptions;
the language used to describe symptoms and changes
over time; the participant’s decision-making and triggers
to help seeking; and the experience of the diagnostic
process of primary and secondary care from the patient
perspective. A calendar-landmarking technique19 was
used as an adjunct to the interviews, to establish the
timing and details of events which led to the melanoma
diagnosis, together with diaries and letters that partici-
pants referred to during this process. Participants were
also invited to make a pencil drawing/s of their skin
cancer as it developed; ongoing analyses are examining
perceptions of lesions over time and comparing the
drawings with clinical images. At the end of each inter-
view, participants completed a short questionnaire to
provide demographic data and information about their
skin and hair colour and their skin’s response to ultra-
violet (UV) light using the widely validated Fitzpatrick
Scale.20
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Interviews were undertaken as soon as possible after
diagnosis, with all interviews completed within 10 weeks
of diagnosis and the majority within 6 weeks. Interviews
lasted between 40 and 65 min and were conducted pri-
marily in the participant’s home, although two people
chose to be interviewed in university ofﬁces. Patients were
sometimes accompanied by a family member, usually
spouse or daughter. Audio-recordings of interviews were
professionally transcribed verbatim and anonymised.
Analysis
All interview transcripts were repeatedly read and
re-read by the two researchers LB (nursing background)
and DC (health services researcher), and the members
of the ‘core’ analysis team also read the majority of the
transcripts (FMW, academic GP; SS, health psychologist;
CC, primary care researcher). Analysis was an iterative
process starting near the beginning of data collection
and using the 17 pilot interviews to develop our analytic
strategy. We used the approach of Framework analysis to
create and establish meaningful patterns in ﬁve phases,
namely: familiarisation with the data, generating initial
codes, inductively searching for themes among codes,
index charting and mapping of data, before ﬁnally
deﬁning and naming themes.21 The coding and data
management were supported by NVivo software (QSR
International, V.9). The Model of Pathways to Treatment
(ﬁgure 1) was also used to underpin the analysis with a
theoretic model for the different intervals and processes
that occur along the pathway to diagnosis and treatment,
in order to accurately assess the time intervals, their
content and context. The ﬁnal themes were agreed
through a series of meetings involving all ﬁve ‘core’
researchers, and a consensus meeting with the wider
study team.
The analysis focused on the main themes within the
time to presentation (TTP), deﬁned as from the ﬁrst
detection of skin change to the ﬁrst consultation with an
HCP.22 23 This interval comprises the appraisal and help-
seeking intervals,17 18 and the analysis examined patient
and healthcare factors as well as ‘disease’ factors, relat-
ing to the developing melanoma. When the ﬁrst consult-
ation did not result in a referral, we also included
further iterative processes until the next consultation in
the analyses. Participants with shorter intervals tended
to use diaries and have good recall of the relevant dates.
People with longer intervals tended to have vaguer recol-
lections, particularly around the time they had ﬁrst
detected any skin change. While participants were often
able to discuss triggers to help seeking, they were less
able to recall the precise dates of these triggers, and we
therefore do not present the separate durations of the
appraisal and help-seeking intervals.
We went on to examine our themes by comparing nar-
ratives from participants diagnosed with thinner and
thicker melanomas and by the melanoma types within
these groups. We further validated our themes by exam-
ining the whole dataset stratiﬁed by gender, age (less
than 60 vs 60 and over, and 80 and over), educational
level (no further education vs further education) and
geographical location (Cambridge vs Edinburgh).
Credibility was increased by the two researchers together
undertaking coding and producing code tables through-
out the analytic process, and reaching consensus from
the potentially wide range of interpretations across the
‘core’ analysis team.
Figure 1 Model of Pathways to Treatment (HCP, healthcare professional).
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RESULTS
A total of 241 adult patients were approached to take
part in this study (Cambridge 114, Edinburgh 127), 121
were willing to participate (50%: Cambridge 53%,
Edinburgh 47%), and 63 were interviewed.
Patient characteristics
Table 1 shows the demographic and self-reported skin
characteristics of the 63 study participants and the clin-
ical characteristics of their melanomas, comparing parti-
cipants with thinner (n=33, median Breslow thickness
0.5 mm, range 0.1–0.9 mm) and thicker (n=30, median
Breslow thickness 3.5 mm, range 2.1–12.0 mm) melano-
mas. While people with thinner melanomas were
younger (60.5 vs 66.1 years), the groups were otherwise
similar for sociodemographic factors. One quarter of
the group reported a family history of melanoma, while
eight participants reported previous skin cancer (melan-
oma 2, basal cell carcinoma 6); we were only able to
verify the two melanomas with histology reports. The
thinner melanomas were all histologically reported as
superﬁcial spreading melanomas (SSM) and lentigo
maligna melanomas (LMM) apart from one diagnosed
as part SSM and part NM (nodular melanomas; ‘other’).
Table 1 Characteristics of study participants (n=63), and clinical characteristics of their melanomas, comparing thinner
(n=33) and thicker (n=30) melanomas
Thinner melanomas
(<1 mm Breslow thickness)
Thicker melanomas
(>2 mm Breslow thickness)
Age at interview
Mean age±SD (range) 60.5±14.6 (29–85) 66.1±15.5 (36–93)
Less than 60 years (n=23) 14 (61%) 9 (39%)
60 years and over (n=40) 19 (47%) 21 (53%)
Gender
Male 14 (42%) 17 (58%)
Female 19 (58%) 13 (42%)
Education
No further education 21 (64%) 21 (70%)
Further education 12 (36%) 9 (30%)
Fitzpatrick scale: skin colour*
Type I (white skin, very fair) 7 (21%) 2 (6%)
Type II (white skin, fair) 6 (18%) 11 (37%)
Type III (creamy white, any hair) 17 (52%) 16 (53%)
Type IV (brown, Mediterranean) 3 (9%) 1 (3%)
Fitzpatrick scale: skin reaction to sun*
Type I (always burns, never tans) 4 (12%) 3 (10%)
Type II (usually burns, tans with difficulty) 11 (33%) 10 (33%)
Type III (sometimes mild burn, gradually tans) 10 (30%) 11 (37%)
Type IV (rarely burns, tans easily) 6 (18%) 6 (20%)
Type V (very rarely burns, tans very easily) 2 (7%) 0
Melanoma location
Head and neck 6 (18%) 9 (30%)
Trunk† 9 (27%) 4 (14%)
Upper limb 10 (30%) 7 (23%)
Lower limb 8 (24%) 10 (33%)
Melanoma type
Superficial spreading melanoma (SSM) 25 (76%) 10 (33%)
Nodular melanoma (NM) 0 10 (33%)
Lentigo maligna melanoma (LMM) 7 (21%) 2 (7%)
Others‡ 1 (3%) 8 (27%)
Melanoma TNM stage
I§ 33 (100%) 0
II¶ 0 23 (77%)
III** 0 7 (23%)
IV 0 0
*Self-reported, not verified in medical records.
†Includes melanomas on the back (thinner 6, 18%; thicker 3, 10%).
‡Thinner: mixed type (SSM and NM)×1; thicker: LMM 2, acral 1, malignant blue naevus 1, unclassified 6.
§Stage IA=27, stage IB=6 (T1–2a, N0, M0).
¶Stage IIA=11, stage IIB=5, stage IIC=7 (T2b–4b, N0, M0).
**Stage IIIA=6, stage IIIB=1 (T1a–4a, N1a–2c, M0).
LMM, lentigo maligna melanomas; NM, nodular melanomas; SSM, superficial spreading melanomas; TNM, TNM Classification of Malignant
Tumours (TNM system).
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Owing to our sampling strategy there was a higher preva-
lence of nodular melanomas than in reported local
ﬁgures. However, only a third of the thicker melanomas
were NM (n=10), while a third were SSM (n=10), and
the remaining third had ‘other’ diagnoses (LMM 2,
acral 1, malignant blue naevus 1, unclassiﬁed 6). Of the
nine participants diagnosed with melanoma on their
back, seven were male, and three had thicker melano-
mas (NM 2, SSM 1).
Duration of skin changes
Four participants (male 3, female 1) had their melano-
mas diagnosed opportunistically by an HCP (3 GPs, 1
oncologist); all these were thinner melanomas. The TTP
was between 1 and 303 weeks (thinner: median TTP
21 weeks, range 1–303 weeks, 5 longer than 52 weeks;
thicker: median TTP 19 weeks, range 1–156 weeks, 7
longer than 52 weeks). Most participants who presented
with skin changes were referred after their ﬁrst primary
care consultation. The remainder were referred after
their second consultation (n=11); none reported more
than two consultations prior to referral. Comparisons
between those with thinner (n=4) and thicker (n=7)
melanomas who were referred after a second primary
care consultation are presented in table 3 and discussed
later (see section on Healthcare providers and system
factors).
The main emerging themes within the appraisal and
help-seeking intervals are discussed below. Throughout
this section quotations are accompanied by information
about gender (male (M), female (F)), age, melanoma
group (thinner or thicker), type of melanoma (SSM,
NM, LMM, other) and symptom duration as TTP in
weeks (including ﬁrst and second presentations).
The appraisal interval
The 59 participants who detected their melanoma them-
selves described a variable and complex process of
appraisal and reappraisal of their skin, against their
background knowledge of ‘normal skin changes’ and
potential risk factors. We found no evidence of differ-
ences between people with thinner and thicker melano-
mas across any of these themes.
Patient factors
Explanations for skin changes
Awareness of a skin change, either a new lesion or a
change in an existing lesion, did not usually cause any
initial concern as it seemed so innocuous, and was often
attributed to normal life changes such as pregnancy or
aging.
I didnt recognise it as something that was different,
because Ive got quite a few moles on my skin so therefore
I thought, Has this been here before, or am I just imagin-
ing that I havent seen it before? [F, 68, thinner, SSM,
52w]
Perhaps because Id been pregnant and everything was
darker anyway or you know, I didnt take any notice.
[F, 36, thicker, NM, 17w]
Other explanations were also often made, such as an
insect bite or injury when the participant had been
outside or in the garden.
Since Id been outside to a barbeque and I thought, oh
well Ive been bitten, its just bitten there on the mole.
[F, 54, thicker, SSM, 1w]
Skin changes were sometimes attributed to another
skin condition (such as psoriasis) if it presented in a
similar way; in these cases participants’ previous experi-
ences of a benign condition could inﬂuence their per-
ception of the potential seriousness of the new skin
changes.
Prior beliefs about melanoma and its risk factors
Skin changes were appraised within the context of
peoples’ prior beliefs about melanoma and its risk
factors, and their life experiences. Participants often
used the terms skin cancer and melanoma interchange-
ably, and their prior awareness of melanoma varied
widely. Whereas some participants noted that they had
no awareness at all, others described gaining some
knowledge about melanoma via TV programmes, maga-
zines, the internet, and occasionally, health promotion
material. A minority had heightened awareness through
the melanoma experience of a family member or friend,
or even a celebrity. A family history of melanoma or a
personal previous melanoma led several people to have
heightened risk perception and awareness and to
quickly identify skin changes as a potential melanoma;
all these people sought help rapidly and presented with
thinner melanomas.
I wouldnt have known what they were talking about.
[M, 62, thicker, SSM, 52w]
Because my mum has had a melanoma ten years ago so
Ive always been aware to keep a check on my moles.
[F, 29, thinner, SSM, 3w]
Many participants showed some understanding of the
risk factors associated with melanoma and/or skin
cancer when they discussed having lived in hot climates,
or having suffered from sunburn, especially as a child.
However, some were quite certain that they had never
exposed themselves to the risk of UV damage.
I thought I had been careful about sitting out in the sun.
[F, 57, thicker, NM, 36w]
Prior knowledge or experience of melanoma and its
risk factors did not appear to be related to educational
levels, nor to melanoma thickness at diagnosis.
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Do skin changes ‘match’ a melanoma?
While some participants admitted to prior knowledge of
the symptoms and signs of a melanoma, such as ‘jagged
edges’ or change in colour, only a few people had
known that an itchy or bleeding mole was a ‘bad’ sign.
Only two people noticed a match between their
observed skin changes and their mental image of a mel-
anoma, and this match appeared to prompt appropriate
help seeking, leading to shorter TTP.
I dont know when I learnt it, but it was just in my subcon-
scious that ooh I need to go and, its an itchy mole, thats
not good. [M, 45, thicker, SSM, 4w/52w]
Strikingly, the majority of participants reported that
their observed skin changes did not match their mental
image (which had arisen from the melanoma experi-
ence of a family member or friend, from written and
visual images, or from their knowledge of other cancers,
see box 1). When the changes did not match their
mental images, people appeared more likely to ‘normal-
ise’ their skin changes, or adopt other explanations, thus
delaying help seeking and diagnosis. Thus, the appraisal
interval was often prolonged when there was a ‘mis-
match’ between the mental image people had of melan-
oma and the way in which their own skin changes
developed.
Disease factors: skin changes
Most participants used rich and vivid lay vocabularies to
describe their skin changes, for example, “like a black
ﬂy squashed on a mirror” (M, 48, thinner, SSM, 2w).
Table 2 shows descriptions of skin changes noticed by
participants, displayed according to the items of the
Glasgow seven-point checklist (7PCL).24 It also gives
descriptions not commonly found on checklists. For
instance, many people reported surprise at the small
size of their melanoma, describing it as ‘just a little
spot’. Some also reported a ‘spot on a mole’, or that
their skin change had been ‘always there’ or a ‘new
lesion’; a few reported their lesion as ‘different to the
others’ (resonating with the Ugly Duckling sign25).
Overall, table 2 shows that thinner and thicker mela-
nomas can show any of the changes described in the
7PCL. However, there is a suggestion of slightly different
patterns. In particular, patients with thicker melanomas,
both NMs and SSMs, described the so-called ‘minor fea-
tures’ of bleeding, oozing and itch more often. They
also described both horizontal and vertical growth,
again, irrespective of pathological type. Patients with
thinner lesions discussed changes in shape more often.
We were not able to ﬁnd any differences in descriptions
of skin changes between gender, age, educational level
or geographical region.
The help-seeking interval
Reasons for waiting before seeking help included weigh-
ing up the priority of their skin change against other
commitments. Many participants had been encouraged
by other people to seek the advice of an HCP for their
skin change. Emotions such as fear of a serious condi-
tion, cancer or treatment were seldom mentioned and
seemed to play little part in most people’s decision-
making, either to promote or delay help seeking. More
were concerned about going to see their GP with only
minor symptoms, and wasting the GP’s time.
Box 1 Illustrative quotations of a ‘mismatch’ between
observed skin changes and ‘mental images’ of a melanoma
Comparison with experience of a family member’s melanoma
‘My mother in law had skin cancer on her back, so I expected
melanoma to be much bigger: my little mole was nothing.’ (F, 53,
thinner, SSM, 14w/52w)
Comparison with information
‘I suppose from the descriptions that I’ve read about melano-
mas... it didn’t ring any alarm bells… Okay, it has to start some-
where but, as it developed, (I expected) it would become more
raised, it would be scaly and rough, it would be more
inflamed-looking. But because this just remained completely flat
on the skin…it didn’t meet any profile that I was expecting’.
(F, 63, thinner, LMM, 104w)
‘It’s not like a mole, you can see a mole changing colour or
shape or texture, you can read all about that, but as my wife says,
nothing in the leaflets says anything about under the nail’.
(M, 60, thicker, other, 1w)
‘Because melanomas, he says, are black. Now, this growth on my
knee, it was just like a warty growth, with a scarlet top on it,
and... there was no discolouration in it at all…I think that’s
maybe how a lot of folk’ll not think of these things, because it
doesn’t look like what you think it’s supposed to be, if you ken
what I mean. It’s just like a bit of skin rising up’. (M, 52, thicker,
SSM, 42w)
Comparison with images
‘I think that the way melanomas are publicised, this is what they
look like, that’s really misleading ’cos that isn’t what mine looked
like until I saw it blown up on (the dermatologist)’s screen, and I
thought ‘oh my God, yeah, mine does look like one of the ones
on the front of the leaflet’ but… it just looks very neat, symmet-
rical, you know, sharp edges’. (F, 39, thinner, other, 78w)
‘When you go to the hospital and you see the things on the walls,
and on the internet, and you see the diagrams of it, that is to me
what malignant melanoma looks like. Mine didn’t look… it just
didn’t come into the category of melanoma, it hadn’t (gone)
funny shaped, it hadn’t been jaggy, it didn’t go dark, it didn’t get
bigger…it just wasn’t what I imagined melanoma to look like. I
think of (melanoma) getting bigger, crustier, bleeding … and this
was… dead flat… none of the things that were there at the back
of my mind actually rang any alarm bells’. (F, 58, thinner,
SSM, 22w)
‘It didn’t look like a melanoma. Even the booklet I’ve got given
since… four or six pictures in there of actually different ones and
it didn’t look like one of them…Even like the doctor said “I’ve
noticed it on there before but I didn’t take any notice”’. (M, 36,
thicker, NM, 78w/3w)
Comparison with knowledge of other cancers
‘I think if I could feel pain and know what it was, I may be more
responsive to getting it treated’. (M, 74, thinner, LMM, 303w)
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Table 2 Descriptions of skin changes, using the Glasgow seven-point checklist (7PCL) criteria36 and other descriptions (dis-confirming reports in pink)
Feature - Subgroups
Way feature was described Thinner Thicker
Thinner Thicker
SSM
n=25
LMM
n=7
Other
n=1
NM
n=10
SSM
n=10
LMM/
Others
n=10
1 7PCL criteria
1.1. Changing size
i Cover more skin
ii Raised from skin
‘it had grown, it looked bigger’ (M,48,SSM,2w) ‘getting bigger, but not ultra-big, no-one noticed’ (M,66,
other,136w)
● ● ● ● • ●
‘dark brown part was .. more raised’ (F,40,SSM,3w) ‘vertical before it curved across at the top’ [M,45,SSM,4w/
52w), ‘mushroomed out… bubbled up’ [M,78,NM,8w)
• ● ● ●
No changing size- flat to skin ●
1.2. Changing and/or
irregular shape
‘it sort of made.. a pinky horseshoe’ [F,53,SSM,14w/
52w), ‘maple-leaf raggedy’ [F,63, LMM,104w)
‘breaking into several bits’ [F,48,other,4w/78w) ● ● ● • ●
No changing shape- smooth edge •
1.3. Changing and/or
irregular colour
‘two colours, dark with a lighter section’ [M,37,
SSM,52w), ‘slight discolour that got darker, black like
oil’ [M,67,SSM,208w)
‘red then turned black, lively-looking’ [M,73,other,104w),
‘several different colours’ (M,82,other,3w)
● ● ● ● ● ●
No changing colour (not always darker) • • • •
1.4. Oozing
i Bleeding
ii Discharge
‘a new shaving blade would nick it but didn’t bleed on
its own’ (M,74,LMM,303w)
‘noticed blood on the pillow’ (M,66,NM,78w), ‘forever
bleeding and getting a scab’ (M,86,SSM,52w)
• • ● ● ●
- ‘thick oozy matter’ (M,91,NM,60w) • • •
1.5. Changing
sensation i Itch
ii Soreness
‘when it felt itchy and I peeled like flaked off bits of it’
(M,67,SSM,208w)
‘it was within a mole, just the smallest pimple, a red itchy
spot (M,45,SSM,4w/52w)
• • ● •
‘when caught my nail on it a little bit sore’ (F,40,
SSM,3w)
‘painful sort of like a wasp sting’ (M,60,NM,1w) • • • ●
1.6. Inflammation
i Texture change
ii Crusty, flaky
‘quite bumpy’ (M,63,SSM,2w/104w) ‘bubbled up’ (M,78,NM,8w) • • ● ●
‘it was very dry, a bit scaly’ (F,37,SSM,8w) ‘dark leathery, I tried to keep it moisturised’ (F,48,other,4w/
78w)
• • ● • •
1.7 Large size ‘larger than a mole, about the size of a one penny
piece’ (F,66,LMM,20w/78w)
‘size of a thumb nail’ (F,63,LMM,104w)
‘It was like a 2p piece’ (M,82,other,3w)
‘felt this huge lump’ (M,40,other,4w/68w)
• • • • ●
2 Other descriptions
2.1 ‘Different’ ‘look very different from all the others’ (M,63,SSM,2w/
104w)
‘not like the rest of my moles’ (F,37,SSM,8w)
‘quite a big mole, nothing wrong until the spot on top’
(F,54,SSM,1w), ‘two were different, more livelier than the
other ones’ (M,73,other,104w)
• •
2.2 Small size
i Tiny/small mole
Ii ‘just a spot’
‘tiny, wee circular mole’ (F,43,LMM, 22w)
‘a little black spot, just an aging spot’ (F,76,LMM,16w)
‘it was so minuscule’ (M,93,LMM,22w)
‘it was nothing like a mole at all, it was just like a spot’
(M,64,other,20w)
● • ● ● ●
2.3 New lesion ‘somebody else has noticed it so it must be a new one’
(F,43,LMM,22w)‘the mole had appeared, it was a new
mole’ (F,29,SSM,3w)
‘just suddenly appeared’ (F,57,NM,36w)
‘came very quick; it wasn’t there and then it was there’
(F,76,SSM,4w)
● ● • ● ●
2.4 ‘Always there’ ‘had been there for literally years’ (M,74, SSM,14w), ‘a
birthmark, heart shaped, an old friend’ (F,39,other,78w)
‘been there from birth’ (F,56,NM,10w/16w)
‘always had that mole, it didn’t bother me’ (F,61,SSM,26w)
● ● ● ● ● ●
Reported feature per group: •=1–25%; ●=25–50%; ●=50–75%; ●=75–100%.
F, female; LMM, lentigo maligna melanomas; M, male; NM, nodular melanomas; SSM, superficial spreading melanomas; w, week.
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Patient factors
Prioritisation choices
Many participants discussed other responsibilities in their
lives which felt more important than making an appoint-
ment to consult their GP about a skin change, and therefore
contributed to delays in help seeking. These competing pri-
orities included employment, care of family members,
moving house, holidays and other health concerns.
In the cab game you can’t organise things, you can’t
afford to be off your work. [M, 66, thicker, other, 156w]
The six year old has got ADHD and mild autism and he’s
hard work, and I suppose [you’re] concentrating on him
most of your life like, and don’t think about yourself…
[M, 36, thicker, NM, 78w/3w]
I’d been very busy with selling a house, buying a house,
all the rest of it, and of course I’ve patients as well to see.
[F, 72, thinner, SSM, 8w]
I had an ulcer on my leg, and redressing that, so I think I
was more taken up with that getting healed... [F, 76,
thicker, NM, 4w (Community nurse contacted GP)]
Some people mentioned repeatedly failing to make an
appointment with a HCP either because of the compet-
ing responsibilities or because a skin change was ‘not a
priority’:
I was supposed to have phoned up, but I forgot because
it was busy at work and… it just skipped my memory. [M,
59, thinner, SSM, 1w]
I didn’t class it as an emergency…I didn’t think it was
important enough… [M, 64, thicker, other, 20w]
We found no differences in prioritisation choices
between people with thinner and thicker melanomas.
Influence of other family members and the social network
Many participants had been encouraged by other people
to seek medical help, either by an observation about the
skin change itself, or an encouragement to make an
appointment with their GP (see box 2). Some partici-
pants had not been aware of their skin change until it was
noticed by another person; others had known, and were
also often aware that it was continuing to change, but
they were ultimately encouraged to seek help by others.
The other people included family members, friends,
work colleagues and people providing treatments such as
beauty therapists and hairdressers. The promotion of
help seeking, whether by family members or friends, did
not appear to affect TTP overall, but may have acted as a
trigger for many people. A few people were wrongly reas-
sured by family members or friends that their skin
change was not potentially serious. This appeared to
delay timely help seeking. There was no evident differ-
ence in the inﬂuence of family members between people
diagnosed with thinner or thicker melanomas.
Triggers for help seeking
The main difference between participants with thinner
and thicker melanomas was apparent with the ‘triggers’
that people described as they moved from the appraisal
to help-seeking interval, when they realised that they
‘had a reason to discuss their skin change with a, HCP’
(see ﬁgure 1). While most people from both groups
consulted family or their wider social network for
endorsement to seek help about aspects of skin changes
(changing colour, texture and size), some people with
thinner melanomas also reported a heightened aware-
ness of cancer from family experiences or the non-
medical media, or noticing their skin changes as ‘differ-
ent to normal’, while participants with thicker melano-
mas appeared to depend on prompts such as the more
‘red ﬂag’ symptom of oozing/bleeding.
Box 2 Illustrative quotations of the influences of com-
ments from extended family and friends
Noticing a skin change
‘My partner’s daughter says to me ‘Have you always had that
mole on your ear?’ So I thought well somebody else has noticed
it so it must be a new one’. (F, 43, thinner, LMM, 22w)
‘I saw my sisters at the funeral and they both mentioned it; we
hadn’t noticed it’. (M, 66, thicker, NM, 78w)
Acting on encouragement to seek help
‘It wasn’t till my daughter-in-law come over from Australia, and
she said to me that she thought I ought to have it checked out
because obviously in Australia they’re very conscious of it all’.
(F, 58, thinner, SSM, 22w)
‘The girl in the beauty salon… she always asked me about this
one… and then I went again and she said, ‘have you seen a
doctor?’, I said, ‘no, I don’t because it’s nothing, I feel okay’, and
she said, ‘no, please, I will make you a cup of tea, I will give you
a phone number, please go this week’. (F, 40, thinner,
SSM, 156w)
‘I was at a dinner with my daughter, and fortunately I had a low
backed dress on, and one of her friends said, “I don’t like the
look of that mole on your back, and I suggest you have it checked
out”’. (F, 66, thicker, SSM, 4w)
‘It dinnae change dramatically, so one day I quietly said to nurse
friend, “Will you just have a look at this for me?” She just took
one look and she says “You must promise me when you get
home you will go and see the doctor”’. (F, 61, thicker, SSM, 26w)
Advice of others having little effect
‘She thought it was getting darker at some stage, can’t remember
exactly when, but she maybe nagged me for a year or two
before’. (M, 67, thinner, SSM, 208w)
‘It’s not as if I hadnae been told to go and see about it, because
my daughter and my wife… they said, ‘Well you should go and
see about that,’ but I never did, you know, until May’. (M, 64,
thicker, other, 20w)
Not encouraging help-seeking
‘Fairly early on I discussed it with (a friend)… But because she
said, “I can’t really feel it” I think I ignored it. It would have been
better if she’d said to me, “I think you need to have it looked at.”
I think I’d have gone to the doctor then, but because she said,
“No, I think it’s fine” I think I left it’. (F, 64, thicker, LMM, 104 w)
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It was a black mole and most of my moles are dark or light
brown so it was a different colour. [F, 29, thinner, SSM, 3w]
I’d seen something on that Embarrassing Bodies pro-
gramme, and they did a thing about moles and what was
not right and so I suppose I saw that and that sort of
made me think, maybe I should go and get it looked at.
[F, 54, thicker, SSM, 1w]
It started to bleed, that was the point at which I went to
the doctor ’cos I thought it shouldn’t be bleeding. [F, 64,
thicker, LMM, 104w]
Healthcare providers and system factors
Issues concerning healthcare providers and the NHS
were only mentioned by a minority of participants. The
ﬁrst and most important area of concern involved a
group of participants (n=11; thinner=4 (SSM 3, LMM 1);
thicker=7 (SSM 2,NM 3, acral 1, blue malignant naevus 1)
who reported that they had previously shown their lesion
to an HCP, and had been reassured that they did not
need further treatment (see table 3). While some just
made a passing reference to their ﬁrst, reassuring
encounter with their GP, others gave far more detailed
descriptions. A ﬁrst encounter often appeared to delay a
second visit to the GP by providing ‘false reassurance’
about the lesion. Some mentioned that they had not
been adviced (oral, written or a website) on how to best
monitor their lesion and what changes should alert them
to return to their GP; this could potentially result in
thicker lesions at diagnosis.
When people have told you that it’s okay… I sort of took
me eye off the ball really because I thought, well, they
know better than I do. [M, 75, thicker, SSM, 1w/17 w]
Some people had problems with accessing their
general practice for an appointment and, for a few busy
people, this problem was exacerbated by having compet-
ing priorities.
Trying to get an appointment with the GP here can just
be horriﬁc and because I’m out on the road... I have to
plan these things a couple of weeks ahead. [F, 40,
thinner, SSM, 3w]
A few people with thicker melanomas also mentioned
a dislike of seeing doctors, either in general practices or
hospitals, so this might have delayed help seeking.
I’m just not a hospital person or a doctor person. If I’m
really ill, I ken I’ll have to go, but I have to be that way.
[M, 52, thicker, SSM, 42w]
Patients’ concerns about ‘wasting their GP’s time’ are
well known, but this concern appeared to be exacer-
bated by the small size of the skin changes and the lack
of pain or other features that could signify more serious
conditions. Again, this concern appeared more preva-
lent among people with thicker than thinner
melanomas.
My decisions on going to the GP are always inﬂuenced to
some extent by a knowledge of how busy they are and
not wanting to waste their time. [F, 48, thicker, other,
4w/78w]
I think most people that I know would be afraid of the
doctor saying to himself or herself, you know, there’s
people just coming for nothing at all. [M, 93, thicker,
LMM, 22w]
A 56-year-old woman diagnosed with a stage IIIA
nodular melanoma on her lower leg described her
pathway over 6 months as follows:
Appraisal (10w): I’ve always had a mole on my leg... it
was there from birth... it never bothered me because it
was just ﬂat and dark brown… It was possibly about six
months ago I noticed it was just a little bit raised when it
had always been ﬂat... as if like maybe something was
stuck in there…
Table 3 Time from first detecting a skin change to first presentation, and first to second presentations to primary care, by
time intervals (ordered by first TTP), gender, age, melanoma type and stage
Time from detecting a skin
change to first presentation
Time from first presentation
to second presentation Gender and age Type and stage
Thinner melanomas
1 2w 104w M, 63 SSM, IA
2 4w 22w F, 58 SSM, IA
3 14w 52w F, 53 SSM, IA
4 20w 78w F, 66 LMM, IA
Thicker melanomas
5 1w 17w M, 75 SSM, IIC
6 3w 1w M, 73 NM, IIB
7 4w 52w M, 45 SSM, IIA
8 4w 68w M, 40 Other, IIIA
9 4w 78w F, 48 Acral, IIIA
10 10w 16w F, 56 NM, IIIA
11 78w 3w M, 36 NM, IIA
F, female; LMM, lentigo maligna melanomas; M, male; NM, nodular melanomas; SSM, superficial spreading melanomas; w, week.
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Help seeking: I was due to have a smear and... I asked
the nurse to look at it... and she said, Oh no, there’s
nothing to worry about, that’s... I can tell these things, so
she just sort of put my mind at rest... I thought, Well, she
knows what she’s talking about.
Re-appraisal 16 weeks: It just started obviously getting
bigger and bigger. What was the worst was every time I
knocked it, it bled... like a tick on you, because it was big
and bulbous.
Help seeking: I realised it was getting bigger and my
friend and I had talked about it and [I returned to the
surgery]... it was a different nurse more senior, I have
known her for years... she sort of panicked me...saying... I
need to get that looked at straight away.
DISCUSSION
Main findings
This is the ﬁrst study of detailed patient descriptions of
their symptom experience and pathways to diagnosis of
thinner and thicker melanomas in the UK. Addressing
the policy agenda to diagnose melanoma earlier, the
ﬁndings provide a number of novel insights suggesting
where future interventions may be targeted. The key
ﬁnding is that there appear to be subtly different pat-
terns of symptoms experienced by those with thicker
and thinner melanomas. In particular, descriptions of
vertical growth, bleeding, oozing and itch were features
of thicker melanomas irrespective of pathological type.
Furthermore, they did not appear to occur subsequent
to changes in size, shape and colour, nor just be due to
location on the body, for example, not all thicker lesions
were nodular melanomas on the backs of older men.
There was no clear distinction between TTP and melan-
oma thickness. It also does not appear that those with
thicker melanomas have different cognitive, emotional
or behavioural responses to skin changes compared to
those with thinner melanomas, or have different path-
ways to or through the healthcare system. While help
seeking was often postponed because of other life con-
cerns, most decisions to seek help were triggered by
common factors such as advice from family and friends.
We also found a mismatch between the textual infor-
mation and published images currently available, and
the skin changes that were noticed by our participants.
This provides opportunities to incorporate more appro-
priate lay vocabulary and photographic images into tar-
geted community NHS and charity-run awareness
campaigns such as ‘Be Clear on Cancer’ and ‘Detect
Cancer Early’.26 A small but important minority of parti-
cipants did not have their developing melanomas recog-
nised during their ﬁrst primary care consultation, and
were not provided with enough information about
on-going assessment of further skin changes or when to
return to their clinician. These ‘safety-netting’ opportun-
ities could be improved by more systematic approaches
by GPs.
Strengths and weaknesses
Our methodological approaches have a number of
strengths. We do not know of any other studies world-
wide which have compared the patient experience
across the appraisal and help-seeking intervals between
people with thinner and thicker melanomas. We
recruited participants systematically from dermatology
clinics in two contrasting regions over 12 months, and
interviewed all the consenting patients diagnosed with
the much less common melanomas ≥ 2 mm thickness
with a poorer prognosis. The thicker melanoma group
included equal numbers of NMs, SSMs and other rare
and unclassiﬁed types, although no amelanotic lesions;
the diversity of types in this group suggest that the differ-
ences identiﬁed between the thinner and thicker groups
cannot simply be considered due to the biological differ-
ences between SSMs and NMs. Furthermore, using semi-
structured interviews soon after diagnosis reduced recall
bias and allowed participants to speak freely about the
period leading up to their diagnosis.
We used novel and rigorous approaches to data collec-
tion, with the Model of Pathways to Treatment to under-
pin the interview schedule, and four different data
collection methods including the use of patient draw-
ings. Asking people to draw their skin changes and
developing melanomas was of value to a number of par-
ticipants, allowing them to describe subtle changes in
more detail, and also to corroborate the accuracy of
their recall of timing and events. Calendar landmarking
was also of value to a large minority of participants, who
were able to reﬁne their recall of events and time inter-
vals along their TTP.19 Data saturation was reached
before the total sample had been interviewed, suggest-
ing that our ﬁndings are robust and representative of
people diagnosed with melanoma in these regions of
England and Scotland. As recommended in a 2006
review of symptom interpretation as a source of delay in
melanoma presentation,27 we increased the rigour of
our research by applying a theoretical approach (the
Pathways to Treatment model17 18) to frame our data col-
lection and analysis. We conducted and reported this
study according to the Aarhus statement guidelines on
early cancer diagnosis research.22
The main weakness is that the interviews are necessar-
ily retrospective and subject to recall and framing bias.
As a result, the accounts cannot be regarded as an exact
description of what happened. Instead, they are narra-
tives that allowed people to describe their experiences
and reﬂect a post hoc rationalisation of events framed
by their subsequent encounters with HCPs and
increased knowledge since the diagnosis. Although we
recruited all patients with thicker melanomas compared
with purposive recruitment for thinner melanomas we
believe the groups were similar as the latter groups were
matched for gender, age, geographic location and
season. Furthermore, people from these two UK regions
may have different beliefs and experiences of the
pathway to melanoma diagnosis from people in other
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UK regions, and patients who did not agree to take part
in the study may have affected the representativeness of
the sample.
Comparison with the existing literature
While there is a paucity of qualitative studies undertaken
with people soon after their melanoma diagnosis, our
ﬁndings resonate with a grounded theory study under-
taken in northern England that explored the meaning
to people treated for melanoma of shorter and longer
time lapses between detecting signs and receiving treat-
ment,28 and those from an interview study about factors
inﬂuencing presentation in primary care, undertaken
with patients with suspicious pigmented lesions (only 4/
40 interviewees were later diagnosed with melanoma).15
A French questionnaire study set among 590 people
with melanomas also showed that relatives were involved
in the detection of half of the melanomas, with median
delays of 4 months before the patient realised they had a
suspicious lesion, and further median delays of
2 months before this lesion was seen by a doctor.29
Other evidence around time to diagnosis, but not com-
paring thinner and thicker melanomas, comes mainly
from retrospective review of medical records or derma-
tologist experience, and suggests similar times to diagno-
sis and diagnosis.30
Implications for clinicians and policymakers
Policymakers continue to face the challenge of a wide-
spread lack of awareness of cancer symptoms among the
UK general population,31 and that there are the signiﬁ-
cant barriers to help seeking.32 Policy responses have
included campaigns to raise symptom awareness, with
major investment in the new ‘Be Clear on Cancer’ skin
cancer pilot campaign in SW England. Our ﬁndings
clearly demonstrate that the words and images in
current use may not meet the needs of the population
who are likely to be assessing their skin changes at an
early stage in tumour development. Current images tend
to represent more extreme changes which may not
always be present. Future melanoma awareness cam-
paigns, as well as NHS and charity websites giving infor-
mation about skin checks, would be advised to provide
more evidence around the features of early skin changes
using lay vocabulary,33 to consider their selection of
images of early melanomas for a better ‘match’ with
people’s observations, and to provide more evidence
around prompts to encourage timely help seeking. They
should also consider more targeted approaches such as
focusing on: providing higher risk groups such as older
men with tailored information, lay vocabulary and
images; giving families and friends advice on how to
check each other’s skin regularly; and talking with pro-
fessional groups from the hair, beauty, and exercise
industries who also undertake informal skin checks.
Several participants reported visiting their GP or other
HCP on more than one occasion and some were given
false reassurance. The average GP working in the UK
will only diagnose a melanoma every 2–3 years but will
commonly be consulted about a pigmented skin lesion,
often after other health issues have already been dis-
cussed in the consultation. While we recognise the chal-
lenges facing GPs when differentiating potentially rare
and serious conditions such as melanoma from common
and benign conditions, this study suggests that some
patients are not being provided with adequate informa-
tion either about monitoring their skin changes or what
changes should prompt another consultation. The prin-
ciples of ‘safety-netting’ have been disseminated by the
RCGP and could be applied more effectively; they
include recommendations for appropriate advice and
written information for patients about the warning symp-
toms, monitoring symptoms, when to make a follow-up
appointment, and reassurance to patients that symptoms
like skin changes warrant GP attention, thus ‘legitimis-
ing’ a follow-up visit.34
Unanswered questions and future research
While the ﬁndings of this qualitative study are of imme-
diate importance to primary care clinicians and policy-
makers, there are also suggestions of subtly different
patterns of symptoms experienced by those with thicker
and thinner melanomas, irrespective of pathological
type. The descriptions of vertical as well as horizontal
growth, and bleeding, oozing or itch were particular fea-
tures of thicker melanomas but not only NMs.
Furthermore, they did not appear to occur subsequent
to changes in size, shape or colour, so may not necessar-
ily be later features of melanoma. Although these
symptom clusters may be more related to tumour
biology than differences in symptom appraisal and help
seeking, these interesting differences need further
exploration with bigger and more diverse populations
and quantitative as well as qualitative study designs.
Alternative approaches to raising symptom awareness
and supporting monitoring of skin changes to prompt
earlier help seeking may be needed. There is a growing
interest in the application of smartphone technology as
one such approach, and it is clearly an area for further
research,35 but concerns remain around the safety and
utility of this technology.
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